Status:
WITHDRAWN
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
Lead Sponsor:
Tamir Biotechnology, Inc.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD ...
Eligibility Criteria
Inclusion
- Age greater than 18 years
- ECOG less than 2
- Estimated survival of greater than 12 weeks
Exclusion
- Prior systemic chemotherapy for locally advanced or metastatic NSCLC
- Use of any investigational agent within 28 days prior to registration
- Known hypersensitivity to any of the study drugs
- Brain metastases or leptomeningeal disease
- History of prior malignancy within the past three years
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01184287
Last Update
September 2 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Tower Cancer Research Foundation
Beverly Hills, California, United States, 90211
2
Van Andel Research Institute
Grand Rapids, Michigan, United States, 49503
3
Sletten Cancer Specialists
Great Falls, Montana, United States, 59405
4
The Cancer Institute at NYU Langone Medical Center
New York, New York, United States, 10016